Press "Enter" to skip to content

FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups

FDA expands the indication of Vascepa (icosapent ethyl) capsules to reduce the risk of cardiovascular events as an adjunct to maximally tolerated statin therapy in high-risk adult patients with elevated triglyceride levels. It is a fish oil-derived omega-3 fatty acid product indicated to reduce the

Original source:

Also Read:   FDA Announces Collaborative Review of Scientific Evidence to Support Associations Between Genetic Information and Specific Medications